"We have made notable progress in executing our product development and launch strategies throughout 2009, but we have also faced considerable challenges", continued Mr. Owusu-Akyaw. "Our domestic base business grew sequentially compared with the second quarter and year-over-year, which we believe provides tangible evidence that our growth strategy is gaining traction and that we are successfully executing. While we were able to achieve domestic sales growth, we have seen a slowdown in international sales, primarily due to our self-imposed temporary suspension of Bulgarian tissue in a key Asian market and the general economic and reimbursement conditions in Greece. Initially, we anticipated recovering some of the lost market share in the second half of 2009, but we now believe we have lost traction in these markets. For the three and nine months ended September 30, 2009, these markets generated revenue of $.3 million and $2.0 million, respectively, compared with $1.6 million and $5.4 million in the comparable periods of 2008."

Recent and Upcoming Corporate Developments

    --  During the third quarter, Osteotech commercialized FacetLinx Fusion
        Technology for use in facet fusion procedures.  Based upon surgeon
        feedback following the initial introduction, the Company made strategic
        changes to the instrumentation set to enhance the product's ease-of-use.
        Early in the fourth quarter, the Company commenced a limited launch of
        the product and early sales indicate that FacetLinx is quickly gaining
        traction among key surgeons.

    --  Early in the fourth quarter, the Company announced the first U.S. spinal
        surgery using MagniFuse PC (Posterior Cervical), which marked the start
        of the controlled release for the Company's family of products based
        upon the MagniFuse technology platform.  MagniFuse PC was utilized
        during a posterior cervical fusion surgery and was cited as being
        easy-to-use and intuitive with a differentiated self-contained delivery
        system unlike any other product on the market.  Osteotech expects
        MagniFuse technology to be used in 25 procedures by the time of the
        North American Spine Society annual meeting in mid-November.

    --  Osteotech intends to showcase its MagniFuse Technology and FacetLinx
        Fusion Technology at the North American Spine Society annual meeting in
        San Francisco, California from November 10 - 14, 2009.

    --  During the third quarter, Osteotech began the process of analyzing data
        from the 60-patient DuraTech BioRegeneration Matrix clinical trial.
        Based upon the data analysis process, the Company now expects to file
        during the fourth quarter of 2009 a 510(k) application with the United
        States Food and Drug Administration (FDA) to secure marketing clearance
        for DuraTech.  DuraTech is the first of several products under
        development based upon Osteotech's proprietary human collagen technology
        (HCT(TM)) platform.

Financial Results

Revenue for the three months ended September 30, 2009 was $23.0 million compared with $24.1 million for the three months ended September 30, 2008. The decline in revenue for the third quarter of 2009 compared with the same period of 2008 was primarily driven by the expected reduction in revenue from the services businesses. The services businesses include client services and private label demineralized bone matrix, which collectively declined $1.1 million to $.7 million in the third quarter of 2009 compared with the third quarter of 2008. Excluding client services and private label demineralized bone matrix revenue, third quarter 2009 revenues were essentially equivalent with third quarter 2008 revenues. International revenue was $4.6 million, a decline of $.5 million in the third quarter of 2009 compared with the same period of 2008 primarily reflecting the challenging general economic conditions and the lingering impact following the resolution of the Company's self imposed temporary suspension of tissue products processed from tissue recovered by its Bulgarian subsidiary. Domestic revenue in the Company's base business was approximately $17.7 million in the third quarter of 2009 and grew 3% compared with the same period of 2008, and 6% compared with the second quarter of 2009. The Company's base business excludes client services and private label demineralized bone matrix product revenues.

Revenue for the nine-month period ended September 30, 2009 was $70.4 million compared with $79.2 million reported for the same period of 2008. The decline in revenue for the nine-month period ended September 30, 2009 was primarily driven by: the expected reduction in revenue from the Company's services businesses, which declined $5.2 million, the aforementioned decline in international revenue and lower domestic unit sales volume.

Net loss for the third quarter ended September 30, 2009 was $1.9 million, or $0.11 per share, compared with net income of $58,000, or breakeven for the third quarter of 2008. Net loss for the nine-month period ended September 30, 2009 was $4.9 million, or $0.27 per share, compared with net income of $2.6 million, or $0.15 per diluted share, for the comparable period of 2008. The net loss in 2009 is primarily due to the Company's anticipated reductions in revenue and lower gross margins and, in the third quarter, higher-than-anticipated costs related to a variety of enhancements to its new procedure-specific biologic solutions.

Guidance

Based upon the results achieved to date and the additional expenditures the Company expects to incur to support its enhanced launch strategies and product updates, Osteotech is updating the financial guidance it previously established for 2009:

    --  Revenue is expected to range between $92 million and $94 million;
    --  Net loss for 2009 is expected to be between $0.32 and $0.36 per share;
        and

    --  The Company expects to exit 2009 with $9 million to $10 million in cash.

Conference Call Tomorrow, November 6, 2009

The Osteotech management team will host a conference call on November 6, 2009 at 9:00 a.m. (EST) to discuss third quarter 2009 financial results, recent corporate developments and guidance for 2009. The call can be accessed by dialing 1-866-770-7129 (domestic) or 1-617-213-8067 (international) and indicating access code 27776012. The conference will also be simultaneously webcast at http://www.osteotech.com. A replay of the call will be available two hours after completion of the live call through midnight, Friday, November 20, 2009 by dialing 1-888-286-8010 and indicating access code 24133940.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or the conference call, please go to Osteotech's website at www.osteotech.com.

Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of November 5, 2009 and the Company does not intend to update this information.

                              OSTEOTECH, INC. and Subsidiaries
                           CONSOLIDATED STATEMENTS OF OPERATIONS
                       (dollars in thousands, except per share data)
                                         (unaudited)


                               Three Months         Nine Months
                                   Ended               Ended
                               September 30,        September 30,
                             2009       2008       2009       2008

    Revenue               $22,961    $24,063    $70,363    $79,247
    Cost of Revenue        12,502     11,182     36,406     37,622
    Gross profit           10,459     12,881     33,957     41,625

    Marketing, selling and
      general and
      administrative
      expenses             10,648     10,476     33,034     33,479
    Research and
      development
      expenses              1,544      1,739      5,195      5,273
                           12,192     12,215     38,229     38,752

    Operating income
     (loss)                (1,733)       666     (4,272)     2,873

    Interest expense,
      net                    (354)     (276)     (1,063)      (762)
    Other                      58      (270)        106        953

    Income before
      income taxes         (2,029)       120     (5,229)     3,064
    Income tax
      provision (benefit)    (122)        62       (322)       452
    Net Income            $(1,907)   $    58    $(4,907)   $ 2,612
    Earnings per share:
         Basic            $ (0.11)   $     -    $ (0.27)    $ 0.15
         Diluted          $ (0.11)   $     -    $ (0.27)    $ 0.15
    Shares used in
      Computing
      earnings (loss)
      per share:
         Basic         18,120,350 17,881,018 17,925,718 17,749,402
         Diluted       18,120,350 17,993,900 17,925,718 17,854,319



                            CONSOLIDATED SEGMENT REVENUE DETAIL
                                   (dollars in thousands)
                                        (unaudited)

                              Three Months         Nine Months
                                  Ended               Ended
                               September 30,       September 30,
                             2009      2008      2009      2008
    DBM                   $14,611   $14,023   $43,445   $47,564
    Hybrid/Synthetic          894       816     2,289     2,187
    Traditional Tissue      5,101     5,246    15,821    15,606
    Spinal Allografts       1,966     1,943     5,708     6,479
    Client Services           125     1,706     2,013     6,527
    Other Product Lines       264       329     1,087       884
    Revenue               $22,961   $24,063   $70,363   $79,247




                             OSTEOTECH, INC. and Subsidiaries
                           CONDENSED CONSOLIDATED BALANCE SHEETS
                                  (dollars in thousands)
                                       (unaudited)

                                            September 30,      December 31,
                                                 2009              2008
    Assets

    Cash and cash equivalents                   $10,607           $18,823
    Accounts receivable, net                     19,393            17,968
    Deferred processing costs                    45,476            38,715
    Inventories                                   1,683             1,467
    Prepaid expenses and other current assets     2,303             3,115
                 Total current assets            79,462            80,088
    Property, plant and equipment, net           30,894            34,005
    Other assets                                  8,718            13,022
                                               $119,074          $127,115

        Liabilities and Stockholders' Equity

    Accounts payable and accrued liabilities    $19,973           $23,569
    Current maturities of capital lease
     obligation                                     968               895
                 Total current liabilities       20,941            24,464
    Capital lease obligation                     12,439            13,175
    Other liabilities                             6,742             6,626
                 Total liabilities               40,122            44,265
    Stockholders' equity                         78,952            82,850
                                               $119,074          $127,115

SOURCE Osteotech, Inc.

http://www.osteotech.com

CTS is one of the largest tissue banks in the United States, distributing nearly 10% of all tissue grafts in the U.S. and is an accredited member of the American Association of Tissue Banks. CTS is ISO 9001:2000 Registered and is firmly committed to providing the highest quality of tissues for transplantation.

"We are excited to expand our relationship with one of the leading tissue banks in the United States," said Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer. "CTS has a commitment to respecting the gift of life to enhance patient outcomes which is wholly in-line with Osteotech's mission to leverage our technology into life-changing biologic products."

Mr. Owusu-Akyaw continued, "Our goal is to be a vanguard in the development of novel, first-in-class bio-materials that will support and heighten advances in surgical techniques and patient outcomes through the use of innovative procedure-specific biologic products. Through our patented technology platforms, we have successfully begun to introduce a wide variety of advanced biologics with unique regenerative qualities and healing properties."

"At CTS, we strive to be on the forefront of new graft development and we believe Osteotech's commitment to developing new technology that can leverage the gift of life supports our goal. We look forward to our expanded relationship with Osteotech," said David Smith, M.D., Chief Executive Officer of Community Tissue Services.

About Community Tissue Services

CTS is a quality and ethical non-profit provider of services to recipients, donor families, medical communities, and community partners through the respectful recovery, processing and distribution of tissue grafts. CTS, an accredited member of the American Association of Tissue Banks, is one of the largest tissue banks in the United States and operates regional offices in California, Texas, Indiana, Tennessee, Pennsylvania, Oregon and Ohio, and two satellite offices in Idaho and Oregon. For more information on CTS, visit www.communitytissue.org or call 937-461-3364.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients through the development of innovative therapy-driven products that alleviate pain, promote regenerative and biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at www.osteotech.com.

Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of November 4, 2009 and the Company does not intend to update this information.

SOURCE Osteotech, Inc.

http://www.osteotech.com

This new agreement expires in December 2019 and includes one five-year renewal term and subsequent two-year renewal terms subject to six month cancellation clauses.

Owusu-Akyaw, president and CEO of Osteotech, said: "We are excited to expand our relationship with one of the leading tissue banks in the US. CTS has a commitment to respecting the gift of life to enhance patient outcomes which is wholly in-line with Osteotech's mission to leverage our technology into life-changing biologic products."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Go to www.mysmartrend.com now for a FREE two-week trial.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html